Abstract Details

Title Generalizability of the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS-PATHS) Data: Experience from a Single Site

Topic Multiple Sclerosis

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-074

Objective

To evaluate if patients completing neuroperformance testing and enrolled in the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS-PATHS) research project are similar to a general multiple sclerosis (MS) cohort in a large center.

Background The Multiple Sclerosis Performance Test (MSPT) comprises iPad® versions of patient-reported outcomes (PROs) and neuroperformance tests administered in routine care in our practice. MS-PATHS is a multicenter research project collecting real-word standardized clinical data from office visits in MS centers via the MSPT. Enrollment requires patient consent. We evaluated to what extent patients completing MSPT and enrolling in MS-PATHS are representative of the total patient population followed at our center.

Design/Methods

Demographics, disease characteristics, PROs, and neuroperformance test scores (within ±2.5 years) from MSPT database and electronic health records for all established MS patients between January-May 2018 were compared across patients depending on their status: evaluation via MSPT (MSPT+/-) and MS-PATHS enrollment (MS-PATHS+/-) using ANOVA and Pearson's chi-square tests. Significance was set to p<0.01.

Results Of 2560 patients seen (mean age 50.6±12.5 years, disease duration 16.7±11.7 years, 73.4% female, 82.0% white) 86.4% completed the MSPT, and 71.7% enrolled in MS-PATHS. There were no demographic differences between MSPT+ and MSPT- groups. Among MSPT+ patients (n=2211), MS-PATHS enrollees were slightly younger (50.1±12.2 vs. 51.9±12.8 years, p=0.008), had better manual dexterity (30.9±11.8 vs. 33.1±17.0 seconds, p=0.003), and had slightly better processing speed (45.2±13.8 vs. 43.0±14.3 correct answers, p=0.007) than MS-PATHS- patients, whereas race, sex, disease duration, walking speed, low-contrast visual acuity, Patient-Determined Disease Steps score, Patient-Health-Questionnaire-9 score, and Quality of Life in Neurological Disorders sub-scores were similar.

Conclusions

MSPT and MS-PATHS include a high proportion of clinical MS patients and are representative of all patients receiving care at our center. Generalizability of the MS-PATHS data should be further evaluated at a multicenter level.

Authors/Disclosures
Gabrielle Macaron, MD PRESENTER	Dr. Macaron has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Macaron has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Macaron has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Macaron has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD-Serono. Dr. Macaron has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Macaron has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Macaron has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MedEdge. Dr. Macaron has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. Macaron has received research support from National MS Society/International Progressive Multiple Sclerosis Alliance .
	No disclosure on file
	No disclosure on file
Marisa P. McGinley, DO (Cleveland Clinic)	Dr. McGinley has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. McGinley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. The institution of Dr. McGinley has received research support from Biogen. The institution of Dr. McGinley has received research support from Genentech. The institution of Dr. McGinley has received research support from NIH. The institution of Dr. McGinley has received research support from AHRQ. The institution of Dr. McGinley has received research support from EMD Serono.
Jeffrey A. Cohen, MD (Cleveland Clinic)	Dr. Cohen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Convelo. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astoria. Dr. Cohen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viatris. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PSI. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celltrion.
Robert A. Bermel, MD, FAAN (Cleveland Clinic)	Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Bermel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Bermel has received research support from Biogen. The institution of Dr. Bermel has received research support from Roche. The institution of Dr. Bermel has received research support from Novartis. Dr. Bermel has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��